Abstract

BackgroundNanosilver is used in a variety of medical and consumer products because of its antibacterial activity. This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is, however, relatively scarce. In a previous study, the systemic toxicity of 20 nm silver nanoparticles (Ag-NP) was studied in a 28-day repeated-dose toxicity study in rats. Ag-NP were intravenously administered with a maximum dose of 6 mg/kg body weight (bw)/day. Several immune parameters were affected: reduced thymus weight, increased spleen weight and spleen cell number, a strongly reduced NK cell activity, and reduced IFN-γ production were observed.MethodsPrompted by these affected immune parameters, we wished to assess exposure effects on the functional immune system. Therefore, in the present study the T-cell dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) was measured in a similar 28-day intravenous repeated-dose toxicity study. In addition, a range of immunological parameters was measured. Data obtained using the benchmark dose (BMD) approach were analyzed by fitting dose-response models to the parameters measured.ResultsA reduction in KLH-specific IgG was seen, with a lowest 5% lower confidence bound of the BMD (BMDL) of 0.40 mg/kg bw/day. This suggests that Ag-NP induce suppression of the functional immune system. Other parameters sensitive to Ag-NP exposure were in line with our previous study: a reduced thymus weight with a BMDL of 0.76 mg/kg bw/day, and an increased spleen weight, spleen cell number, and spleen cell subsets, with BMDLs between 0.36 and 1.11 mg/kg bw/day. Because the effects on the spleen are not reflected by increased KLH-specific IgG, they, however, do not suggest immune stimulation.ConclusionsIntravenous Ag-NP administration in a 28-day repeated-dose toxicity study induces suppression of the functional immune system. This finding underscores the importance to study the TDAR to evaluate immunotoxicity and not to rely solely on measuring immune cell subsets.

Highlights

  • Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity

  • Clinical chemistry showed an increase in alkaline phosphatase (ALP), aspartate aminotransferase (ALT), and cholesterol, indicating liver toxicity [9,11,13]

  • Immunization resulted in a 2% increase in mean corpuscular hemoglobin (MCH) (P = 0.007), a 4% decrease in hemoglobin distribution width (HDW) (P = 0.046), and a 17% increase in mean platelet volume (MPV) (P = 0.004)

Read more

Summary

Introduction

Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity This wide application results in an increased human exposure. Oral 28-day, oral 90-day, inhalation 28-day, and inhalation 13-week repeated-dose exposure studies did not show severe systemic toxicity of nanosilver [8,9,10,11,12,13]. We have recently performed a 28-day repeated-dose toxicity study [14] in which nanosilver was administered intravenously. This exposure route was chosen in order to avoid the limited systemic exposure due to the cellular barriers present in the GI-tract and lungs. Several immune parameters were affected: reduced thymus weight, increased spleen weight and spleen cell number, strongly reduced NK cell activity, and reduced IFN-γ production were observed

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call